Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | F11 | P03951 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.32 |
| ▸ | CCR2 | P41597 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15051452 | 0.88 | NPC1 (0.48) | NPC1F11MAPTKLKB1DGAT1 | |
| SCHEMBL15050722 | 0.86 | NPC1 (0.40) | NPC1F11MAPTKLKB1DGAT1 | |
| SCHEMBL25254238 | 0.76 | NPC1 (0.40) | NPC1F11MAPTKLKB1DGAT1 | |
| SCHEMBL20597948 | 0.74 | NPC1 (0.39) | NPC1F11MAPTKLKB1DGAT1 | |
| SCHEMBL3111779 | 0.73 | NPC1 (0.33) | NPC1F11MAPTDGAT1 | |
| SCHEMBL3028008 | 0.72 | DGAT1 (0.38) | NPC1F11MAPTKLKB1DGAT1 | |
| SCHEMBL31332415 | 0.71 | NPC1 (0.46) | NPC1MAPTCCR2 | |
| SCHEMBL31332410 | 0.71 | NPC1 (0.46) | NPC1MAPTCCR2 | |
| SCHEMBL24896328 | 0.71 | CCR2 (0.53) | NPC1F11KLKB1CCR2 | |
| SCHEMBL30220549 | 0.71 | CCR2 (0.53) | NPC1F11KLKB1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2793879-A1 | HETEROARYLS AND USES THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013096637-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013096637-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165483-A1 | HETEROARYLS AND USES THEREOF | PIK3R5, PIK3R4, PIK3C2B | NPC1 304/4885F11 4184/4885MAPT 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.